NCT02375880 - Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions

Carcinoma of Intrahepatic and Extra-hepatic Biliary SystemCarcinoma of GallbladderBile Duct CancerCholangiocarcinoma

Interventions

DRUG

DKN-01

Administration by intravenous (IV) infusion.

DRUG

gemcitabine

Administered by IV infusion.

DRUG

cisplatin

Administered by IV infusion

Trial Locations (9)

Columbia University Medical Center, New York

University Hospitals, Case Medical Center, Cleveland

Cleveland Clinic, Cleveland

University of Texas Health Science Center at San Antonio, San Antonio

University of Southern California, Los Angeles

Yale University, New Haven

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston